Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP-701 in FLT-3 Mutated AML
NCT00030186Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lestaurtinib in acute myeloid leukemia (AML), sponsored by Cephalon, Inc.. Started Jan 2002; status: completed.
02
Drugs
lestaurtinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00030186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030186.